Meeting
2014 ASCO Annual Meeting
Response rate and durability of chemotherapy for metastatic Merkel cell carcinoma among 62 patients.
Authors
Jayasri G Iyer
University of Washington, Seattle, WA
Jayasri G Iyer , Astrid Blom , Ryan Doumani , Christopher Lewis , Austin Anderson , Christine Ma , Upendra Parvathaneni , Shailender Bhatia , Paul Nghiem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9091)
DOI
10.1200/jco.2014.32.15_suppl.9091
Abstract #
9091
Poster Bd #
295
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Association between objective responses (OR) and overall survival (OS) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab.
First Author: Sandra P. D'Angelo
Poster
2020 Gastrointestinal Cancers Symposium
A phase II trial of pembrolizumab in combination with cisplatin or carboplatin and etoposide in chemotherapy naive patients with metastatic or unresectable high-grade gastroenteropanncreatic or lung neuroendocrine carcinoma.
First Author: Robert A. Ramirez
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.
First Author: Sandra P. D'Angelo
Poster
2014 ASCO Annual Meeting
Activity of chemotherapy in a series of patients with locally advanced or metastatic pleomorphic rhabdomyosarcoma: A retrospective analysis.
First Author: Michela Libertini